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Abstract
Heart failure has become a real epidemic condition related to poor outcomes despite 
advances in medical therapies. Prevalence of significant mitral and/or tricuspid regur-
gitation is high in patients with advanced heart failure. Novel transcatheter techniques 
have recently emerged as a minimally invasive alternative in patients deemed high-risk 
for surgery or inoperable. Among them, MitraClip® system is thus far the first device that 
received regulatory approval and gained widespread clinical application, especially in 
patients with functional mitral regurgitation. Furthermore, first experiences with new 
devices for percutaneous mitral and tricuspid valves repair, and transcatheter mitral 
valve prosthesis have been increasingly reported. Percutaneous therapies for valvular 
heart disease have therefore become one of the most promising fields in the present and 
future of interventional cardiology and heart failure.
Keywords: mitral valve, tricuspid valve, advanced heart failure, MitraClip®, 
percutaneous edge-to-edge mitral valve repair, Cardioband®, Mitralign®, Carillon®, 
percutaneous tricuspid valve repair, transcatheter mitral valve prosthesis
1. Introduction
Heart failure (HF) is one of the most important causes of morbidity and mortality in developed 
countries [1]. The improvement in care of cardiac diseases has significantly reduced acute 
mortality of this condition, in turn, increasing chronic HF prevalence [2]. Hospitalizations for 
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HF are similarly increasing, resulting in very high costs for national health systems [3]. Despite 
developments in drug therapies and the widespread use of implantable cardiac devices, out-
comes remain poor [4]. Several transcatheter implantable devices have recently emerged in an 
attempt to improve the prognosis and quality of life of such patients. In this chapter, we will 
review the percutaneous treatment alternatives for mitral and tricuspid regurgitation (TR) 
associated with advanced HF.
2. Transcatheter mitral valve intervention in mitral regurgitation
2.1. Functional mitral regurgitation and heart failure. Why a percutaneous approach?
Mitral regurgitation (MR) is one of the most common valvular disease worldwide [5] and its 
frequency is increasing with the age of the population. Functional MR (FMR) is a consequence 
of left ventricular (LV) remodeling with structurally preserved mitral valve (MV) leaflets. 
Significant MR may be present in half of the patients with congestive HF [6] and the develop-
ment of MR after an acute myocardial infarction or in patients with dilated cardiomyopathy 
is associated with an increased risk of developing cardiac adverse events [7–11].
Surgery is the treatment of choice for patients with severe MR who refer symptoms or pres-
ent LV dysfunction (LVD) [12]. However, up to 50% of patients cannot undergo MV surgery 
due to prohibitive surgical risk, usually related to advanced age, LVD or comorbidities [13]. 
Moreover, the proportion of patients with FMR undergoing surgical treatment is even lower 
[14]. Interestingly, open-heart surgery has yielded conflicting results in this sort of patients, 
with a lack of clear survival benefit and high recurrence rates even with modern techniques 
[15–18]. On the other hand, conservatively managed unoperated patients have poor clinical 
outcomes, especially those with FMR, whose mortality can exceed 50% at 5-years follow-up 
[19]. Large series from Duke University has proved that isolated medical management in 
patients with ischemic MR is associated with the highest rates of death after 20 years [20]. 
Thus, patients with FMR managed medically represent a high-risk population with high rates 
of death and readmission for HF [21]. Percutaneous MV therapies are emerging as an alterna-
tive for this population in order to fill a large unmet need.
2.2. Percutaneous mitral valve repair
The MV has a complex structure and its competence depends on the preservation of the 
MV leaflets, the subvalvular apparatus, the mitral annulus (MA) and the LV normal shape. 
Dysfunction of any of these different components may lead to the development of MR [22]. 
In the last few years, several percutaneous devices have been under investigation, addressing 
different anatomical and pathophysiological targets involved in MR [23, 24]. Percutaneous 
ongoing therapies have somehow tried to reproduce any of the already contrasted open-
surgery techniques, such as edge-to-edge MV repair (MitraClip®), undersized annuloplasty 
(Carillon®, Cardioband®, Mitralign®) or chordal implantation (Neochord®). Some of them 
have gained approval for human use and have been tested in small clinical trials (Table 1).
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2.2.1. Percutaneous edge-to-edge mitral valve repair (PMVR): MitraClip®
The MitraClip® system (Abbott Vascular, IL, USA) is thus far the first device that received reg-
ulatory approval and gained widespread clinical application. This device consists of two clip 
arms and opposing grippers, which can be opened and closed against each other in order to 
grasp and gain cooptation of MV leaflets at the origin of the regurgitant jet. The procedure is 
carried out under general anesthesia and using fluoroscopic and transesophageal echo guid-
ance. Once the transseptal access is obtained, the system is advanced across the MV into the 
LV. Once the device is below the leaflets the two arms are opened and the device is retracted 
Device Target of 
therapy
Year of CE 
mark
Current 
number of 
patients 
treated
Surgical 
background
Vascular access
Leaflet 
coaptation
2008 >40,000 Edge-to-edge 
repair
Transfemoral
Chordae 
implantation
2013 >300 Chordae 
implantation
Transapical
Indirect 
annuloplasty
2009 >100 No Transjugular
Direct 
annuloplasty
2015 >100 Flexible ring Transfemoral
Direct 
annuloplasty
2016 >100 Commissuroplasty Transarterial 
retrograde
Table 1. Summary of commercially available catheter-based therapies for PMVR.
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to capture and subsequently closed to increase the coaptation surface of the MV leaflets. The 
clip can be reopened and repositioned if the obtained result is not acceptable. Further clips 
can be placed as needed for optimal MR reduction. The amount of remainder MV tissue and 
resulting increase in transmitral pressure gradient are the main procedural limitations for 
further clip deployment. A second-generation device with improved maneuverability is now 
available.
Transcatheter edge-to-edge MV repair has proven to be a safe and effective technique in 
selected patients with either functional or degenerative MR. Feasibility of the therapy with 
MitraClip® was first demonstrated in the Endovascular Valve Edge-to-Edge Repair Study 
(EVEREST) I trial [25] and subsequently compared with conventional surgery in the random-
ized controlled trial (RCT) EVEREST II [26]. In these studies, stringent echo criteria were used 
to guide the feasibility of device insertion and deployment. However, with increasing experi-
ence more complex valve pathologies can be treated with excellent results [27].
The vast majority of clinical evidence in PMVR is related to MitraClip® and it is currently 
the most advanced available technology for clinical use. In the EVEREST II trial, 184 patients 
were randomized (2:1) to receive MitraClip® therapy and 95 patients to undergo surgical 
MV repair or replacement. Included study population was older than reported surgical 
series of MV repair (mean age 67 years old) and presented higher rates of comorbidities. 
The device proved to be safer than surgery with a significant reduction of major adverse 
events (9.6% versus 57% with surgery, p < 0.0001), although this difference was mainly 
driven by a greater need for blood transfusion with surgery. Conversely, in the intent to 
treat analysis, survival free from the primary endpoint (death, MV surgery and MR > 2+) 
was lower with MitraClip® as compared with surgery (55% vs 73%, p = 0.0007) [26]. Results 
of this trial at 5 years follow-up confirmed the initial results of the study. In those patients 
with an initial successful repair, no differences in mortality or reoperation were found in 
the PMVR arm compared to surgery. The proportion of patients with MR grade 3+ or 4+ at 
5-year follow-up was 19%, just the same observed at 1 year, reassuring the durability of the 
PMVR [28].
2.2.1.1. Real-world candidates for percutaneous edge-to-edge mitral repair
Although most patients included in the EVEREST II trial had degenerative MR, in the sub-
group of patients with LVD and/or FMR, no differences in outcomes were observed between 
MV surgery and MitraClip®, opening a new niche for PMVR. In fact, subsequent observa-
tional studies, have mainly recruited patients with FMR, especially in Europe (Table 2) 
[29–36]. Beyond the learning curve, real-world reported results showed increasing rates 
of procedural success over 90–95%, compared to initial experience in the EVEREST I and 
II trials. Furthermore, observational published registries have reported very low short-
term adverse events and consistent improvements in symptoms, quality of life and MR 
reduction. Cohorts included in the main European registries may draw the profile of the 
current prototype of patient candidate for PMVR: advanced age, high-surgical risk, FMR 
and frequent history of ischemic heart disease, LVD and implantable stimulation device 
therapies (Table 3).
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2.2.1.2. Special subsects of patients candidates for MitraClip
2.2.1.2.1. Non-responders to cardiac resynchronization therapy
MitraClip® has also been proved to be a useful tool for those patients with HF not respond-
ing to cardiac resynchronization therapy (CRT) [37]. Auricchio et al. reported their experi-
ence with 51 patients who were severely symptomatic despite CRT therapy. In this cohort, 
PMVR was associated with a significant reduction in MR, clinical improvement and favorable 
remodeling echocardiographic parameters during a median follow-up of 14 months.
Study Type of study Number of 
patients treated 
with MitraClip®
Location 
(number of 
sites)
Enrollment 
years
Functional MR 
(%)
Procedural 
success (MR  
≤ 2+) (%)
EVEREST I 
[26]
Feasibility  
trial
24 USA (11) 2003–2005 21 74
EVEREST II 
[28]
RCT 184 USA (37) 2005–2008 49 77
EVEREST II 
HR [55]
Registry 351 USA (38) 2007–2014 70.1 85.8
ACESS-EU 
[29]
Registry 567 Europe (11) 2009–2011 77 91.2
MitraSwiss 
[30]
Registry 100 Switzerland (4) 2009–2011 62 85
Armoiry et al. 
[31]
Registry 62 France (7) 2010–2012 74 88.2
SENTINEL 
[32]
Registry 628 Europe (25) 2011–2012 72 95.4
TRAMI [33, 
34, 52]
Registry 1064 Germany (20) 2010–2013 71 95.2
MARS [35] Registry 145 Asia (8) 2011–2013 54 94
STS/ACC TVT 
[36]
Registry 564 USA (61) 2013–2014 14 93
Table 2. Main multicenter trials and registries of PMVR.
Appropriate candidates Other potential candidates
Functional mitral regurgitation Acute ischemic mitral regurgitation
Severe left ventricular dysfunction Hemodynamically unstable
High-risk for conventional surgery or inoperable Low probability of successful surgical repair
Prior cardiac surgery (CABG) Falling surgical ring
Non-responders to cardiac resynchronization therapy Advanced heart failure
Table 3. Profile of patients that should be considered for PMVR.
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2.2.1.2.2. End-stage heart failure
The effect of MitraClip® in patients with end-stage HF was reported by Franzen et al., analyz-
ing the treatment of 50 patients with LV ejection fraction (LVEF) ≤ 25%, MR ≥ 3+ and severely 
symptomatic (NYHA III–IV) [38]. The acute procedural success was 94%, and 92% of patients 
were discharged with MR ≤ 2+. One month mortality was 6% (predicted by EuroScore 34%). 
At 6-month follow-up, 72% patients were in functional class NYHA I or II; there was inverse 
remodeling on echo follow-up and a relevant reduction in BNP levels. Several reasons may 
account for these results: first, the positive hemodynamic changes observed after treatment 
with reductions in pulmonary pressure, capillary wedge pressure and increase in cardiac 
output (CO). Second, the avoidance of the low CO post MV surgery; and third, the favorable 
remodeling in LV [39–41]. However, patients with very poor LVEF are at high-risk of mortal-
ity even with this thearpy. Careful selection of these candidates based on operators’ experi-
ence, probability of success and expected benefits is strongly advisable [34].
2.2.1.2.3. Acute ischemic mitral regurgitation
Acute ischemic MR is a severe complication associated with high rates of morbimortality even 
when surgically corrected [42]. MitraClip® has proved to be a safe and effective alternative to 
surgical intervention in these unstable patients [43, 44]. Acute MR usually develops in a previ-
ously normal MV and therefore anatomical features are optimal for PMVR. Rapid improve-
ment in patient’s hemodynamics and the avoidance of the systemic inflammatory response 
associated with cardiopulmonary bypass are potential advantages of transcatheter approach 
[45]. MitraClip® implantation could be considered as an urgent therapy during admission in 
patients with recurrent pulmonary edema and/or cardiogenic shock in which MR is deemed 
to be the main cause of decompensation [46].
2.2.1.2.4. Failing annuloplasty rings
Undersized annuloplasty is currently the standard approach for MV surgical repair [47]. Even 
with the modern prosthetic mitral rings, long-term durability is a major concern in patients 
with FMR, in which the risk for recurrence can be over 50% at 2 years [48]. These patients 
are frequently symptomatic, with an increased number of hospitalizations, and present often 
significant LVD. Series from Italy and Spain have proved that the use of the device is safe 
and produces a persistent reduction in MR, hemodynamic improvement and symptom relief 
[49, 50]. Therefore, MitraClip® should be considered as an alternative therapy in this sort of 
patients, given the unacceptable high-risk that may carry reoperation.
2.2.1.3. Expected benefits from percutaneous edge-to-edge repair
2.2.1.3.1. Persistent reduction in mitral regurgitation
Persistent MR reduction is one of the main goals of PMVR. The target proposed since the 
EVEREST trials is to achieve a reduction of mitral insufficiency to a degree ≤2+ and this has 
been considered as a definition for procedural success (PS) and an acceptable result during 
follow-up [25]. Interestingly, the EVERST II trial was the one with the lower PS reported (77%) 
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[26]. The use of a single clip in almost all the patients and the fact that the trial was conducted 
in the beginning of the learning curve of most centers may explain the lower efficacy of the 
device compared to surgery. With increasing following experience, PS has raised to over 90% 
of cases in most series, highly impacting the prognosis of patients [29, 32–34, 51, 52]. A per-
sistent MR reduction is linked to better outcomes and “the less MR possible” should be the 
target of all procedures [53]. Conversely, inability to reduce MR is an independent marker 
of adverse prognosis [32, 34]. The mechanisms supporting this observation are likely to be 
related to the hemodynamic changes observed after MR correction [39, 40]. Recurrence of 
significant MR is around 6–21.1% at 1 year [29, 32]; notably similar figures are reported with 
surgical repair for ischemic FMR [18].
2.2.1.3.2. Symptoms improvement
Symptomatic improvement is one of the most reported benefits of this therapy. Preprocedure 
patients are usually highly symptomatic with proportions of NYHA functional class III–IV 
over 85% in published series. After treatment with MitraClip®, there is a significant recovery 
in the functional capacity with patients presenting on NYHA functional class I–II in a range 
of 63.3–86% [29, 32, 34, 54, 55]. Furthermore, patients as well experience improvement in 6 
minutes-walk test [29] and quality of life [54, 56], and a significant reduction in serum BNP lev-
els [38]. Clinical improvement does also lead to a significant reduction in readmissions for HF, 
which reduces costs of patients’ health care and might probably turn into better prognosis [55].
2.2.1.3.3. Survival advantage
Survival of patients with FMR treated with MitraClip® is in the range of 15.3–20.3% within the 
first year [29, 32, 34]. The largest follow-up reported showed an actuarial survival at 3 years 
of 74.5% [55].
The available evidence to date regarding this issue relies mainly on retrospective studies. The 
first published was the EVEREST high-risk study [57], where 78 patients with high-surgical 
risk (STS ≥ 12%) were treated with MitraClip® and compared with a cohort of 36 patients 
managed medically. At 1 year, MitraClip® patients have significant higher survival rates (76% 
PMVR vs. 55% medical therapy, p = 0.045). In a study by Swaans et al. [58], 139 patients treated 
percutaneously were compared to 59 patients medically treated. After controlling by propen-
sity score matching, MitraClip® was associated with a relative reduction in the risk of mor-
tality of 59%. In another paper, Velazquez et al. [59] compared the outcomes of 351 patients 
included in the EVEREST high-risk registry with a historic comparator cohort. Two-hundred 
and thirty-nine propensity-matched patients in each group were analyzed and MitraClip® 
was associated with a 1 year improved survival (mortality 22.4% MitraClip® vs. 32% medical 
therapy, p = 0.043). The relative risk reduction in mortality associated with the device was 
34%. Finally, Giannini et al. [60] included 60 patients treated with MitraClip® and propensity 
matched with 60 patients with OMT. After a median follow-up of 515 days, patients treated 
with PMVR showed less mortality, less cardiac mortality and less readmissions due to heart 
failure (log-rank test p = 0.007, p = 0.002 and p = 0.04, respectively). While we wait for the 
final confirmation of these results in currently ongoing RCTs, this information encourages the 
application of the therapy.
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2.2.1.3.4. Effect on heart remodeling: mitral annulus and left ventricle
Reverse LV remodeling is the ‘holy grail’ of PMVR. Reported results from surgical series of 
primary MR have been linked to better prognosis [61]. Echo reports from EVEREST trial have 
demonstrated that there is an inverse remodeling after a successful MitraClip® procedure 
involving both the left chambers (ventricle and atrium) [62]. Interestingly, the magnitude 
of the reverse remodeling is greater with greater reduction in MR and this positive effect is 
maintained at 5 years follow-up [28]. Similar findings were reported in the EVEREST high-
risk cohort [55, 57], although, in these series, patients with LVEF below 25% and severe LV 
dilation (LV end-systolic diameter > 55 mm) were excluded. By contrast, real-world FMR 
patients treated with MitraClip® tend to exhibit poor or no remodeling at all [32]. One possible 
explanation for these conflicting results is that real-world patients are treated too late in the 
natural history of the chronic HF disease, when the LV is largely dilated and LVEF is severely 
depressed. These patients are less likely to show reverse remodeling and this is a hint for the 
best timing for PMVR.
Although PMVR with MitraClip® reproduces somehow the Alfieri procedure, traction forces 
within MV may also favor MA remodeling. Recent studies have demonstrated that in FMR, 
the MA size (anteroposterior diameter), the MA area and the tenting area are significantly 
reduced after device implantation [63]. Furthermore, this reduction is associated with an 
improved functional status at 6 month after the procedure [64]. Conversely, in primary MR, 
MA parameters remain stable after clipping. Therefore, the potential association of an indirect 
annuloplasty-like effect may improve mid-term results of this therapy in patients with FMR.
2.2.2. Percutaneous chordal replacement: Neochord®
Neochord® (Neochord, Minnesota, MN) are the first ePTFE chordal loops conceived to be 
implanted on the MV leaflets to correct flail or prolapse [65]. Colli et al. reported the results of 
transapical off-pump mitral valve implantation of Neochord in 62 patients with MV prolapse 
[66]. Thirty-day major adverse events included one acute myocardial infarction (2%) and two 
cases of sepsis (3%). MR at 30 days was grade 1+ or 2+ in 55 patients (88.7%).
2.2.3. Transcatheter mitral valve annuloplasty (TMVA): Carillon®, Cardioband®, Mitralign®
Annuloplasty is the most common surgical repair performed to treat MR [47]. This technique 
is widely used as a stand-alone procedure to enhance MV coaptation in FMR or added to 
leaflet repair in degenerative MR in order to improve durability [67]. Based on prior large sur-
gical experience, some percutaneous novel devices have tried to reproduce undersized MV 
annuloplasty to address dilatation of the MA. A reliable TMVA has the potential to improve 
outcomes in combination with edge-to-edge repair in selected patients and to increase thera-
peutic alternatives in patients with anatomic ineligibility for MitraClip®. As a further potential 
advantage, unlike the MitraClip®, this approach preserves the native valve anatomy, thus 
keeping the option for future valve implantation open. In fact, some of the annuloplasty 
rings may actually serve as a dock for the anchoring of available transcatheter aortic valves 
 (“valve-in-ring” procedure).
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2.2.3.1. Carillon®
The coronary sinus (CS) encircles approximately two-thirds of the MA, in close relation to the 
posterior and anterior MV leaflets. This was the rationale for the first catheter-based devices 
that aim to achieve an indirect annuloplasty through the cannulation of the CS. The Carillon® 
Mitral Contour System (Cardiac Dimension, Inc., Kirkland, WA, USA) obtained the CE mark 
in 2011. This deformable annular system is implanted in the CS and can reduce the septolat-
eral diameter of the MA by postimplant cinching [68]. The procedure can be easily performed 
under fluoroscopic guidance through a jugular vein access and without general anesthesia. 
Nevertheless, some limitations have hampered the development of this technique. Advance 
imaging studies have demonstrated that the location of the CS is no coplanar to the MA, but 
basally displaced into the LA [69]. Moreover, potentially serious complications have also been 
reported, including compression of the circumflex artery or damage of the septal conduction 
system [70]. Finally, the lack of prior surgical background for the CS approach may be a con-
cern as regards the long-term outcomes of this procedure.
To date, published evidence is limited to a couple observational studies. In the Titan trial, 
only 36 of 53 (67.9%) patients underwent permanent system implantation due to transient 
coronary compromise or reduction of MR < 1+ (recapture of the device was carried out in 
those cases) [71]. Rates of death at 1 and 12 months in this study were 1.9 and 22.6%. In 
the TITAN II trial, the system was successfully implanted in 30 of 36 (83.3%) patients, and 
30-day and 1-year reported mortality were 2.8 and 23%, respectively. Both trials showed that 
device implantation was related to a significant reduction in MR, and to clinical improvement 
and reverse LV remodeling in patients with FMR and HF during up to 24-month follow-up. 
Ongoing REDUCE trial will compare the device to OMT in HF subjects with FMR, thus, pro-
viding further evidence of the potential benefits of this technology.
2.2.3.2. Cardioband®
Cardioband® (Valtech, Inc, Or Yehuda, Israel) is the transcatheter device that most closely 
resembles surgical direct annuloplasty technique. The system consists of a flexible annulo-
plasty band that is delivered from a transseptal approach and implanted onto the atrial side 
of the MA. This incomplete Dacron ring is attached in a supraannular position with multiple 
spiral anchors from commissure to commissure under transesophageal echo and fluoroscopic 
guidance. After implantation, the Cardioband® length can be shortened in order to improve 
leaflet coaptation and reduce MR.
Although flexible partial rings have failed in this sort of patients when implanted surgically 
[72], initial clinical experiences with Cardioband® are promising, confirming the feasibility 
and safety of the device implantation [73]. The CE Mark Trial has enrolled high-risk subjects 
with symptomatic FMR despite OMT. Early outcomes of this trial in 31 patients at 1 month 
showed a significant reduction in the septolateral dimension of the MA in all but two patients 
(36.8 ± 4.8 vs. 29 ± 5.5 mm, p < 0.01) and an increased leaflet coaptation surface [74]. Following 
Cardioband® adjustment (29 of 31 patients), MR was none or trace in 6 (21%), mild in 21 (72%) 
and moderate in 2 (7%) cases. Procedural mortality was zero and in-hospital mortality was 6.5% 
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(2 of 31 patients, neither procedure nor device-related). At 30 days, 22 of the 25 patients (88%) 
had MR grade ≤ 2+. Following results of this trial showed persistent reduction in MR (92% MR 
≤ 2+) and improvement in functional class (77% NYHA I–II) at 24-month follow up. Reported 
procedural success rate (reduction in at least one grade in MR at discharge) was 86%. In 2017, an 
RCT comparing Cardioband® versus stand-alone OMT will start recruiting in the USA.
2.2.3.3. Mitralign®
The Mitralign® (Mitralign, Inc., Tewksbury, MA, USA) is a transcatheter direct annuloplasty 
system that mimics the Kay-Wooler commissuroplasty [75]. The device allows selective plica-
tion of the medial and lateral aspects of the MA by deploying pairs of transannular “pled-
gets”. The procedure is carried out from a transfemoral retrograde approach under live echo 
and fluoroscopic guidance. Each pledget pair can be pulled together resulting in a segmental 
posterior annuloplasty [76]. In the CE Mark Trial, the system was successfully implanted in 
70.4% of 71 high-risk subjects with FMR [77]. No intraprocedural death occurred, but four 
(8.9%) patients experienced cardiac tamponade. 30-days and 6-month reported all-cause mor-
tality were 4.4 and 12.2%, respectively. Significant improvements in MR and clinical func-
tional class, reduction in MA dimensions and LV remodeling were demonstrated at 6 months.
2.2.4. Transcatheter multimodal approach for mitral regurgitation
One of the lessons learned from heart valve surgery is that a combination of diverse techniques 
addressing different mechanisms of MR may improve long-term outcomes [67]. Recently, first 
experiences of direct and indirect TMVA after failure of PMVR with MitraClip® have been 
published [78, 79]. MitraClip® is currently the most widespread technique that focus on MV 
leaflets, with contrasted effective results. Nevertheless, reported recurrence of significant MR 
can surpass 20% at 1 year [29]. Notably, transcatheter mitral rings may play a role as valuable 
adjunct catheter-based procedures to Mitraclip® (or percutaneous chordal replacement) in 
selected patients (such as very dilated LA and MA).
2.3. Transcatheter mitral valve replacement (TMVR)
The simpler structure of the aortic valve (AV) has probably facilitated the success of a stent-
like transcatheter approach for the treatment of AV disease. On the contrary, the much 
more complex structure of the MV may explain the slower way to find a safe and effective 
alternative for TMVR. Many companies have completed first-in-human cases; however, no 
devices are currently approved beyond compassionate use, and several others remain in 
preclinical development. These percutaneous MV prostheses vary either in the access site, 
the design and the anchoring technology within the MA or the subvalvular apparatus [80] 
(Figure 1). Currently, eight different devices have been already implanted in-human since 
2012 (CardiAQ®, Neovasc Tiara®, Edwards Fortis®, Tendyne®, Twelve®, Navigate®, Highlife®, 
Caisson®) [81–84]. These initial experiences showed heterogeneous rates of morbidity and 
mortality across different platforms and pointed out some important challenging issues that 
might be determinant in the development of this technique: the LV outflow obstruction, the 
delivery profile and the access route (transapical vs transeptal). Interestingly, patients with 
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poor ejection fraction presented the higher rates of adverse outcomes and might not benefit 
from this procedure.
Recently, promising results from the Tendyne® feasibility trial have been published [85]. In 
this study 30 high-risk patients (mean age 75.6 years) with predominantly FMR (76.6%) grade 
3 or 4 underwent TMVR. Successful device implantation was achieved in 28 patients (93.3%). 
No acute major cardiovascular adverse events were reported. One patient died 13 days after 
TMVR from hospital-acquired pneumonia and prosthetic leaflet thrombosis was detected in 
one patient at follow-up. At 30 days, transthoracic echocardiography showed mild central MR 
in 1 patient, and no residual MR in the remaining 26 patients with valves in situ. A significant 
decrease in LV dimensions was documented. Seventy-five percent of the patients reported 
mild or no symptoms at follow-up. Successful device implantation free of cardiovascular 
mortality, stroke and device malfunction at 30 days was 86.6%.
3. Percutaneous therapies for tricuspid regurgitation in heart failure
3.1. Functional tricuspid regurgitation
Functional tricuspid regurgitation (TR) represents over 90% of cases of TR and it is typically 
due to tricuspid annular dilatation (mainly in anteroposterior diameter) and right ventricular 
(RV) enlargement (leading to leaflet tethering) secondary to progressive left heart disease 
(LHD) [86]. The tricuspid valve (TV) has been considered for years the “forgotten” valve. This 
Figure 1. Current mitral valve platforms under development.
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issue may be explained by the fact that TR was believed to be well tolerated and reduced after 
treating LHD. On the contrary, patients with significant TR and HF tend to be highly symp-
tomatic due to decrease in CO and abdominal and peripheral congestion [87]. Furthermore, 
the presence of moderate or severe TR is independently associated with an increased mortal-
ity (over 25% at 1 year) regardless of biventricular function or pulmonary pressures [88, 89].
Despite surgical treatment of LHD, significant TR can be found in over two-thirds of patients 
in long-term follow-up, suggesting that a lower threshold for TV repair should be considered 
when MV surgery is carried out [87, 90–92]. Current data support that TV repair at the time 
of MV surgery is safe, whereas reoperation for persistent TR is related to high morbidity 
and mortality rates [93–95]. Notwithstanding, few patients undergo TR surgery and the vast 
majority are managed medically. Data from the STS database suggest that moderate to severe 
TR is present in almost 2 million of patients in the United States, but not even 10,000 undergo 
TV surgery each year. Progressive RV dysfunction may lead to an irreversible RV damage, 
which is thought to be the reason for the poor outcomes of late surgery in this scenario. 
Therefore, there is a large unmet clinical need for patients with significant TR who are not 
referred for conventional surgery, mainly due to expected high-surgical risk. Percutaneous 
therapies for functional TR are emerging as an alternative to surgery in this scenario. Patients 
with symptomatic severe TR and prior open-heart surgery and those with significant TR and 
progressive RV dysfunction and failure despite OMT may benefit from transcatheter TV inter-
ventions. Initial experiences include the off-label use MV devices and first-in-human cases of 
dedicated new technologies [96] (Table 4). Among different therapies that have been tested 
in preclinical setting, transcatheter TV annuloplasty, resembling different successful surgical 
techniques, might be one of the most promising approaches [97, 98].
3.2. Transcatheter tricuspid valve interventions
3.2.1. Percutaneous tricuspid valve repair with mitral valve dedicated devices
The acquired experience in catheter-based therapies for MV with satisfactory results has 
emerged the appealing concept of using some of these devices in tricuspid position. Recently, 
Braun et al. have reported first series of edge-to-edge TV repair in 18 patients with moderate 
to severe functional TR and right-sided heart failure [99]. Six patients were treated for isolated 
severe TR, whereas 12 patients were treated concomitantly to PMVR. A reduction of at least 
one TR grade was achieved in all patients and no in-hospital major events were reported. 
A significant improvement in TR was observed (TR ≥ 3+ 94% vs. 33%, p < 0.001) and sixteen 
patients (89%) referred an improvement in NYHA functional class at 30-day follow-up. In 
2015, the first-in-human transcatheter TV repair with Mitralign® system was published, repro-
ducing Kay posterior annuloplasty [100]. Recently, acute results of Trialign® early human use 
were reported. A single pair of pledgets was successfully implanted in 14 of the 16 patients 
(87.5%), with an average postprocedural reduction of 37% in TA and 59% in TV regurgitant 
orifice area. No procedural mortality occurred. Potential advantage of additional pledgets 
will be assessed. Cardioband® has been also successfully implanted in TA in humans [101] 
and European CE mark study (TRI-REPAIR) is currently initiated.
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Device Features Strengths Challenges
Bicuspidization of the 
tricuspid valve
First series reported
Large experience in 
mitral valve
Friendly to operators
Vascular access route
Modified clipping 
technique
Three-leaflets 
configuration of the valve
Annular dilatation not 
addressed
Bicuspidization of the 
tricuspid valve (posterior 
commissure)
First series reported 
Ongoing CE mark trial
Surgical background
High safety profile
Risk of leaflet or right 
coronary artery injury
Technically demanding
Transesophageal echo 
guidance
Valvular tissue properties
Flexible-ring 
annuloplasty
First in-human cases 
reported
Ongoing CE mark trial
Surgical background Little experience in mitral 
valve
Risk of right coronary 
artery injury
Simple indirect 
annuloplasty
Ongoing CE mark trial
Surgical background
High safety profile
Fully retrievable before 
stenting
Risk of leaflet or right 
coronary artery injury
Inferior vena cava 
dilatation
Semi-rigid complete ring 
implanted in the atrial 
side of the tricuspid 
annulus
First in-human cases 
reported
Surgical background
Repositionable & 
retrievable
Risk of atrioventricular 
block
Valve spacer to fulfil 
regurgitant orifice
First in-human cases 
reported Ongoing CE 
mark trial
Good preliminary 
clinical results
Surgical pocket
Large devices needed to 
fill coaptation gap
No surgical background
Table 4. Catheter-based therapies for TR that have been already tested in humans.
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3.2.2. Transcatheter tricuspid valve repair therapies
TriCinch® (4Tech Cardio, Galway, Ireland) consists of a steerable catheter with a corkscrew at the 
tip. Under echocardiographic and fluoroscopic guidance, supraannular fixation of the device is 
carried out in the mid part of the anterior TA. Afterwards, the catheter is tensioned in order to 
produce TA cinching, therefore reducing the anteroseptal dimension of the TA and improving 
leaflet coaptation. Finally, a self-expandable nitinol stent is positioned at the inferior vena cava in 
order to secure the system and maintain the tension applied. TriCinch® implantation preserves 
the native anatomy, allowing potential future treatment options. First in-human cases [102, 103] 
and early results from the PREVENT CE trial have been reported. The system was successfully 
implanted in 13 of 18 patients (72%). Two patients developed periprocedural hemopericardium 
and device TA detachment was observed in two patients. No mortality events occurred during 
up to 29 months follow-up. A significant improvement in 6-minute walk test and quality of life 
were documented, although only 37.5% remain in NYHA class I–II during this period.
3.2.3. Other percutaneous approaches for tricuspid regurgitation
The FORMA® Repair System (Edwards Lifescience, Irvine, USA) is a valve spacer created to 
increase coaptation surface by occupying space in the regurgitant orifice of the TV. The device 
is usually delivered through a transsubclavian venous route and anchored to the RV apex 
distally and proximally fixed within a small surgically prepared pocket. Preliminary results 
in seven high-risk patients with severe TR and advanced NYHA functional class III–IV were 
recently available [104]. The device was successfully implanted in all patients without major 
complications, obtaining at least one grade acute reduction in TR. 30-day results showed clini-
cal improvements (100% NYHA class II) and stable TR reduction (100% moderate TR) with-
out significant tricuspid stenosis.
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